S
evere subarachnoid hemorrhage (SAH) is frequently followed by cerebral blood flow (CBF) disturbances, particularly cerebral vasospasm (1, 2) . Vasospasm may induce a significant and threatening reduction in CBF, causing secondary ischemic lesions, which peaks on days 5-7 from the bleeding (1, 2) . For this reason, among others, patients affected by vasospasm may benefit from sedation during the ischemic phase, to minimize cerebral metabolic rate of oxygen (CMRO 2 ) (1). Also, vasospasm therapy is oriented toward the maintenance of an adequate CBF, thus a sedative agent capable of increasing CBF while decreasing CMRO 2 may be a valid therapeutic adjunct.
Volatile anesthetics, including isoflurane, are potentially attractive in this direction because they produce a dose-dependent increase in CBF while causing a reduction in CMRO 2 , the combination of the two results in a partial alteration of the flow-metabolism coupling (3) (4) (5) (6) (7) .
The increase of CBF caused by isoflurane is a complex phenomenon because it induces a redistribution of regional CBF (rCBF) within the brain regions. Some authors (8, 9) showed an increase in rCBF predominantly in the anterior and the medial cingulated gyrus and in the insula; other studies (10) , more in the infratentorial gray matter.
The vasodilating effect of isoflurane is the foremost reason for its rare use as a sedative agent in the neurointensive care unit (NICU) because the clinicians fear a potential increase in intracranial pressure (ICP) caused by the increase in CBF. Furthermore, major technical issues such as air pollution and the need of dedicated ventilators have been limiting factors in the use of volatile anesthetics as sedative agents in the intensive care unit (ICU). Today, sedation in the ICU using a volatile anesthetic is feasible using the Anesthetic Conserving Device (AnaConda, Hudson RCI, Uppland Väsby, Sweden), that has been proven to be safe, cost effective, and can be employed in the ICU without causing significant air pollution (11) (12) (13) (14) (15) . Objective: Isoflurane is a volatile anesthetic that has a vasodilating effect on cerebral vessels producing a cerebral blood flow increase. Furthermore, it has been shown in animal studies that isoflurane, when used as a preconditioning agent, has neuroprotective properties, inducing tolerance to ischemia. However, it is not routinely used in neurointensive care because of the potential increase in intracranial pressure caused by the rise in cerebral blood flow. Nevertheless, subarachnoid hemorrhage patients who are at risk for vasospasm may benefit from an increase in cerebral blood flow. We measured regional cerebral blood flow during intravenous sedation with propofol and during sedation with isoflurane in patients with severe subarachnoid hemorrhage not having intracranial hypertension.
Design: The study is a crossover, open clinical trial (NCT00830843).
Setting: Neurointensive care unit of an academic hospital.
Patients: Thirteen patients with severe subarachnoid hemorrhage , (median Fisher scale 4), monitored on clinical indication with intracranial pressure device and a thermal diffusion probe for the assessment of regional cerebral blood flow. An intracranial pressure >18 mm Hg was an exclusion criterion.
Interventions: Cerebral and hemodynamic variables were assessed at three steps.
Step 1: sedation with propofol 3-4 mg/ kg/hr; step 2: after 1 hr of propofol discontinuation and isoflurane 0.8%; step 3: after 1 hr of propofol at the same previous infusion rate. Cerebral perfusion pressure and arterial Pco 2 were maintained constant. Mean cerebral artery flow velocity and jugular vein oxygen saturation were measured at the end of each step.
Measurements and Main Results: Regional cerebral blood flow increased significantly during step 2 (39.3 ± 29 mL/100 hg/min) compared to step 1 (20.8 ± 10.7) and step 3 (24.7 ± 8). There was no difference in regional cerebral blood flow comparing step 1 vs. To assess the real capacity of isoflurane and to increase rCBF in SAH patients, we decided to compare rCBF, cerebral, and hemodynamic variables during traditional intravenous sedation with propofol and during volatile sedation with isoflurane in SAH patients in the early phase of their NICU stay.
MATERIALS AND METHODS
The study is a prospective, crossover, open clinical trial in a controlled setting.
The Institutional Review Board has approved the study and it has been registered in the ClinicalTrials.gov registry (NCT00830843). The Board also approved waiver of written informed consent. However, the Board's procedure required a written informed consent from the patient's next of kin. The written informed consent was obtained after a meeting that occurred between the family and the investigators, and after that an information sheet was given to the next of kin.
Study inclusion criteria were:
-A diagnosis of SAH, within 72 hrs from the initial bleeding. , and core temperature (monitored by a bladder sensor). -A normal ICP (<18 mm Hg) without medical therapies prior to the study.
We excluded the following from the study:
-Patients aged <18 yrs.
-Patients affected by intracranial hypertension, i.e., having an ICP >18 mm Hg prior to the study.
ICP was either monitored with an intraparenchymal microsensor (Codman, Johnson and Johnson Professional, Randolph, MA) or by an external ventricular catheter (EVD, Dispomedica, Hamburg, Germany). rCBF was measured using thermal diffusion probes (Thermal Diffusion Probe, QFlow 500 CBF microprobes Bowman Perfusion Monitor, Hemedex, Cambridge, MA), connected to a Hemedex Bowman perfusion monitor. Probe placement was 2-2.5 cm subdural in the white matter of the vascular territory estimated to be at risk for ischemia. Indication for monitoring was based on the clinical decision in every case. Intermittent monitoring of jugular vein oxygen saturation (SjvO 2 ) and mean cerebral artery (MCA) flow velocity was done by transcranial Doppler (Looki TC, Atys Médical, France).
Cerebral, hemodynamic, and respiratory variables were assessed at three protocol steps:
-Step 1 (Basal, T0): Standard sedation with propofol, 3-4 mg/kg/hr. Because the AnaConda system (AnaConDa) adds a significant dead space to the ventilator circuit that may cause an important raise in PaCO 2 , the system was inserted in the ventilator circuit before the first step (without starting isoflurane) and minute ventilation was adjusted consequently, to maintain constant PaCO 2 . The AnaConda system remained on the ventilator circuit during all the protocol steps. The only difference is the on/off of the isoflurane infusion pump during step 2. -Step 2 (duration 1 hr): Sedation was switched from propofol, 3-4 mg/kg/hr, to isoflurane 0.8 % administered through an AnaConda. Data were recorded after 1 hr. -Step 3: After 1 hr from the interruption of isoflurane and from the resumption of the infusion of propofol at the same previous infusion rate.
An infusion of fentanyl of 0.7 mcg/kg/hr was maintained during all the steps of the protocol.
At the end of each step the values of ICP, CPP, rCBF, and hemodynamic variables were recorded and bilateral MCA velocity and SjvO 2 were measured. Also, cerebral vascular resistance was calculated as CPP/rCBF based at the end of each step (18) .
To avoid confounding effects on rCBF, CPP and arterial pCO 2 were maintained constantly throughout the protocol.
CPP was maintained constant by varying the dosage of vasoconstrictors (norepinephrine), recording doses to assess the impact of the sedatives on arterial pressure stability.
Temperature was measured as core temperature by a bladder sensor that gave a continuous output displayed on the patient monitor.
We decided to perform 1-hr steps to leave sufficient time to the isoflurane administration to reach stability at the desired concentration, and to avoid collecting data just after automatic calibration that occurs in the Hemedex monitor once every hour. Data were collected 10 mins prior to the next calibration.
Primary end point of the study was to assess the variation in rCBF (mL/hg/min) during isoflurane sedation. A population sample size of 13 patients was calculated to have a type I error of 5% and power of 80% presuming a baseline rCBF of 20 ± 5 mL/100 g/ min during step 1 and an increase of 5-6 mL/100 g/min during step 2.
Secondary end point was to assess shortterm safety of sedation with isoflurane, in particular, whether or not sedation with isoflurane produced a significant increase in ICP.
Statistical Analysis. All data are expressed as mean ± sd or as median when not normally distributed (e.g., severity scores). Data were initially analyzed using analysis of Table 1 .
RESULTS
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In all cases, treatment for the ruptured aneurysm was secured within 24 hrs from the hospital access, whereas the study was performed within 56 hrs from the hospital access. Concerning the type of sedation that the patients received prior to the protocol, we had a uniform management. In the ICU, all patients were sedated with propofol and fentanyl for all the time prior to the study with the exception of the routine sedation interruption by the clinician ordered to assess neurologic status. All patients who underwent coiling were sedated with propofol and fentanyl during the procedure. Another variable was the management of patients during clipping. In some patients, the whole procedure was performed under total intravenous anesthesia (still with propofol) while in other patients the anesthetist decided at some point to switch endovenous anesthesia to inhalatory anesthesia with sevoflurane. These patients were then sedated with propofol at the end of the surgical procedure prior to the transfer to the ICU.
In Figures 1-4 , all the measurements taken during the three protocol steps are shown. In comparison to step 1, there was a significant increase of rCBF in all patients in step 2 ( Figs. 1 and 4) . As a consequence, cerebral vascular resistance decreased significantly during step 2 compared to that in step 1. During step 3, we observed a decrease in rCBF in comparison to step 2, but there was no significant difference in rCBF when step 1 and step 3 were compared. Also, SjvO 2 was significantly higher during step 2 compared both to step 1 and step 3 (Fig. 1) .
As planned by the study design, PaCO 2 and CPP were maintained constant during all protocol steps (Fig. 2 ), but we were not able to avoid a slight decrease in core temperature during step 2 when compared to step 1 (Fig. 3) .
Importantly, ICP did not change significantly during the protocol steps. No CSF diversion was necessary to compensate ICP changes during the protocol (Fig. 2) .
No significant difference was observed in the dosing of norepinephrine between the different steps (step 1: 0.09 ± 0.04; step 2: 0.1 ± 0.04; step 3: 0.09 ± 0.03 mcg/ kg/min). Heart rate was significantly higher during step 2 compared to step 3 (step 1: 76.7 ± 12.6; step 2: 83.2 ± 9.9; step 3: 72.7 ± 8.1). Transcranial Doppler taken both on the right and left MCA showed that cerebral blood velocity did not change significantly between step 1 and step 2, and between step 2 and step 3 (Fig. 3) .
DISCUSSION
This study was designed to assess the capacity of isoflurane to increase rCBF in SAH patients sedated with propofol in the early phase of their NICU stay, when the peak of risk of CBF disturbances as vasospasm has not yet occurred. Also, we intended to assess the safety of isoflurane and its effects on ICP in a population of patients not having intracranial hypertension. In our institution, the standard procedure for sedation is to combine a hypnotic agent and fentanyl, to provide adequate sedation and analgesia. To compare the effects of propofol vs. isoflurane, the infusion of fentanyl was maintained constant during the protocol steps, avoiding rebound reactions and surges of pain that could have altered the results. Also, to minimize biases on other factors that could alter CBF, we decided to maintain constant MAP and PaCO 2 during the study.
Within the halogenated volatile anesthetic agents, we selected isoflurane because of its direct effect on cerebral vessels, producing a dose-dependent increase in CBF while causing a reduction in CMRO 2 (3-7), and because its potential neuroprotective effect has been extensively studied in animals in recent years. Furthermore, isoflurane safety profile is good, and in contrast with sevoflurane there is only a low degree of metabolism <1%, in which inorganic fluorides are generated, but do not reach toxic levels with prolonged administration (19) .
The increase in rCBF caused by the onset of isoflurane was significant and occurred in all patients (Fig. 4) . rCBF was lower during step 3 if compared to step 2. rCBF of steps 1 and 3 were not statistically different. It sounds reasonable that rCBF returned to baseline due to the offset of isoflurane. As planned, CPP and PaCO 2 were maintained constant during the protocol. In particular, the rate of norepinephrine infusion at the end of step 2 was not different from step 1. However, the heart rate was higher during step 2 compared to step 3, suggesting that the decrease in peripheral vascular resistance induced by isoflurane was partially compensated by an increase in heart rate.
The onset of isoflurane also caused a decrease in core temperature, presumably caused by peripheral vasodilatation. However, in this setting, a decrease in temperature is a reinforcing element of the capacity of isoflurane of increasing rCBF, given that a higher rCBF was registered at a lower temperature.
Given that rCBF rose during step 2 and CPP remained constant, we obtained a significant decrease in cerebral vascular resistance during step 2. Concerning the characteristics of this decrease, surprisingly, mean MCA transcranial Doppler velocity did not change significantly on both sides during the different steps. A possible explanation of this result could be that isoflurane causes a reduction in cerebral vascular resistance in the microcirculation and in the intraparenchymal arterioles rather than large vessels such as MCA, explored by transcranial Doppler.
This result may sound promising, recent studies suggest that large vessel vasospasm may not be the only factor in predicting outcome in SAH, in particular, intracerebral arterioles have an important role in the regulation of distal CBF (20) (21) (22) (23) (24) (25) .
Another main aspect that appeared in the analysis of the data is the SjvO 2 increase during sedation with isoflurane when compared to sedation with propofol. Different reasons could account as an explanation for this finding. According to the study of Fick's equation, CMRO 2 = (CBF × arterial-venous delivery O 2 ) and SjvO 2 is proportional to the overall relationship between CBF and CMRO 2 . Thus, an increase of SjvO 2 can be explained by an increase in CBF or by a decrease in CMRO 2 , or by a combination of the two. In our study, because we did not have a monitoring system of the depth of sedation we lack the definitive proof of which mechanism is prevalent. However, with both sedatives we applied standard doses for sedation, and the large increase in rCBF may be sufficient to explain the increase in SjvO 2 . Another factor that should be considered concerning the SjvO 2 augmentation is temperature; this was lower during step 2 and could have caused a reduction in CMRO 2 , assuming that the decrease of temperature in the brain causes a reduction in CMRO 2 by approximately 8%-10% per degree Celsius. Again, if this is the case, isoflurane shows that is able to maintain cerebral oxygen balance in favor of oxygen supply, increasing rCBF, and decreasing brain temperature and CMRO 2 , the combination of the two effects could be favorable in SAH patients with dangerous reduction in CBF and the risk of secondary ischemic lesions.
Furthermore, during the previous years a large number of animal studies have been conducted showing the potential neuronal ischemic tolerance induced by isoflurane when used as a preconditioning agent. In vivo, it was demonstrated that preconditioning with isoflurane improves long-term neurologic outcome after hypoxic-ischemic bran injury in neonatal rats (26) (27) (28) , and adult mice (29) , after focal brain ischemia in adult rats (30, 31) . Also, pretreatment with isoflurane increased rCBF and regional oxygen supply in the focal ischemic area in rats (32) .
In vitro, isoflurane postconditioning provided neuroprotection in rat corticostriatal slices (33) , whereas preconditioning induced protection against glutamate neurotoxicity in rat cerebellar slices (34) . Combination of both preconditioning and postconditioning induced a better neuroprotection in a model using rat hippocampal neurons (35) .
The mechanism of the induction of tolerance to ischemia and neuroprotection is still under investigation. Current evidence would suggest that it is inducible nitric oxide synthase dependent (28, (36) (37) (38) (39) . Other factors that could be involved are the suppression of energy requirements, inhibition of excitatory neurotransmission and potentiation of inhibitory receptors, regulation of intracellular calcium responses during ischemia, and the attenuation of ubiquitin-conjugated protein aggregation (36) (37) (38) (39) . Surprisingly, recent animal studies have shown that isoflurane preconditioning response is attenuated by estradiol (40) and that is androgen-dependent in male mice and gender-specific (41, 42) .
The potential of isoflurane for inducing tolerance to cerebral ischemia was studied only in animals and in vitro and needs to be confirmed in human studies. SAH patients at risk for vasospasm could benefit from the administration of a preconditioning agent, given that the ischemic phase usually has its onset 48-72 hrs after the bleeding.
Even if propofol is a drug with a short half-life, it is not reasonable to think that propofol was completely cleared from the blood during the isoflurane step. However, propofol and isoflurane have two distinct mechanisms of action. Propofol is a global central nervous system depressant. It directly activates γ-aminobutyric acid receptors, but also induces the potentiation of γ-aminobutyric acid type A-mediated inhibition of synaptic transmission, and the inhibition of glutamate release (43, 44) . At the same time, propofol is known to decrease CBF, preserving brain flow-metabolism coupling. Thus, even if a residual amount of propofol or emulsion lipids was present in the blood at the moment of the isoflurane step, it should have not mediated an increase in rCBF, whereas it may be that the response to isoflurane could have been attenuated by a residual propofol presence in the blood. Furthermore, in our opinion, the results of step 3 reinforce this hypothesis.
The direct vasodilating effects of isoflurane have limited its use in neurosurgery and in NICU because of the fear of a potential increase in ICP. In our study, we enrolled only patients who were not affected by intracranial hypertension and we did not have a significant change in ICP among the different steps. With these strict entry criteria, we probably selected a population of patients in the favorable part of the cerebral pressure-volume curve, who were capable of accepting an increase of CBF without increasing ICP (45) . Selecting only patients with a normal ICP was a decision oriented to avoid possible harm to patients caused by a raise in ICP consequent to the vasodilatory effects of isoflurane. We acknowledge that this is a strong caveat in the interpretation of our study. Patients who are in a less favorable part of the cerebral pressure-volume curve, i.e., who are in that part of the curve where even a small increase in volume (in our case blood volume) causes a large increase in pressure, may experience a raise in ICP consequent to the raise in CBF and this may have negative effects. Monitoring both ICP and CBF in this situation is essential in choosing the appropriate sedation strategy; we decided to use a thermal diffusion probe technique because it is quantitative, easy to use at the bedside, and has already been validated in the NICU setting (46) .
CONCLUSIONS
Our data suggest that isoflurane is safe and could be used as sedative agent in SAH patients not affected by elevated ICP level, increasing CBF. More studies are needed to confirm the safety of its use and to investigate the real neuroprotective effects of this volatile anesthetic.
